CADTH is inviting stakeholder comments on proposed changes to the patient input template for the CADTH Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR). Patient input is used by CADTH review teams and by the expert committees of the CDR and pCODR programs: the CADTH Canadian ... Read More
13
Sep2016
08
Sep2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2016:
40 negotiations are currently underway with 10 files added since the last update of July 31, 2016:
Cotellic (cobimetinib): used to treat metastatic melanoma
Fabrazyme (agalsidase beta): used to treat ... Read More
26
Aug2016
The Canadian Association for Healthcare Reimbursement (CAHR) is hosting Market Access 201-Fundamentals of Reimbursement in Canada. This one-day training course is a continuation of Market Access 101 and offers a deeper dive into Market Access strategies. The program will be emceed by Dr. Jeffery Hoch from the Department of ... Read More
26
Aug2016
Information Session on the PMPRB Guidelines Modernization Discussion Paper
On August 23rd, 2016, PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, held a free “Information Session on the PMPRB Guidelines Modernization Discussion Paper”. This came shortly after the PMPRB recently releasing its long awaited consultation paper “PMPRB ... Read More
19
Aug2016
2015 Annual Report Released
Earlier today, the Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, released its Annual Report for the year ended December 31, 2015. The Annual Report is an extensive document that reviews all of the PMPRB’s major activities, analyses of ... Read More
17
Aug2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of July 31, 2016:
32 negotiations are currently underway with 2 files added since the last update of June 30, 2016:
Avastin (bevacizumab): used to treat genitourinary platinum-resistant ovarian cancer
Opdivo (nivolumab): used to ... Read More
12
Aug2016
*Tuesday, August 17th Webinar CANCELLED*
We regret to inform you that the webinar session on Wednesday, August 17th, 2016 from 10:00 a.m. to 12:00 p.m. (noon) is cancelled due to unforeseen technical issues. We wanted to give as much notice as possible so individuals can register for the alternate date (Tuesday, ... Read More
10
Aug2016
On June 24, 2016, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”. Are you interested in learning more about the potential repercussions of these changes on Canadian drug prices and implications for pharmaceutical companies?
PDCI Market Access Inc., Canada’s leading pricing and reimbursement ... Read More
05
Aug2016
Results of the Notice and Comment Period on Incremental Reforms to the Compendium of Policies, Guidelines and Procedures
On December 4, 2015, the PMPRB announced the start of a Notice and Comment initiative to seek stakeholder feedback on two proposed amendments to the Compendium of Policies, Guidelines and Procedures: the “Reasonable ... Read More
29
Jul2016
PDCI’s PMPRB Guidelines Modernization Webinar Session
On June 24, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”. The paper, the initial phase of a three-part Guideline modernization process, asserts that PMPRB’s current framework is outdated and seeks feedback on a wide range ... Read More